{"id":"21cd863f-f51a-4164-b958-789b13d40489","arxiv_id":"2412.10337","paper_version":2,"verdict":"CONDITIONAL","confidence":"HIGH","novelty_score":1.0,"correctness_risk":"low","formal_verification":"none","parameter_count":0,"one_line_summary":"A stakeholder-based review of generative AI use cases in medicine and the consent, privacy, transparency, hallucination, usability, equity, evaluation, and accountability challenges that stand between prototypes and safe deployment.","lead":"This paper surveys how generative AI is being used across medicine, grouping use cases by who uses them: clinicians, patients, trial organizers, researchers, and trainees. It then catalogs the main barriers to safe use, from privacy and hallucinations to equity and accountability, and points to open research questions.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Concern: the central summary statistics used to motivate the use cases (88% differential-diagnosis accuracy in Section 2.1, 90% eligibility-criteria reduction in Section 2.3) may not be accurately extracted from the cited studies; the absence of any described literature selection process makes…","rationale":"The stress test agrees with the reader's CONDITIONAL verdict and with the reader's identified weakest assumption: the lack of a described literature selection process. My contribution is to specify exactly which numerical claims are the most load-bearing and most easily checked: the 88% differential diagnosis figure (Section 2.1) and the 90% eligibility-criteria reduction (Section 2.3). The review's abstract and introduction promise a 'comprehensive overview,' and these specific numbers anchor the promise of specific use cases. If those numbers are accurate, the review's usefulness is unchanged. If they are not, the review still functions as a structured entry point, but its central claim of comprehensiveness and its implied prioritization of use cases would require qualification. I therefore keep the verdict unchanged, with the concrete test being a targeted verification of the two headline statistics. No internal inconsistency or outright mis-citation was found in the broader synthesis; the challenge chapters are balanced and well-hedged. The disclosure statement is complete and the review is clearly framed as a narrative review, so a revised version that adds a methods paragraph and positions itself relative to existing reviews would strengthen the claim without changing the core assessment.","tokens_in":27267,"tokens_out":1896,"duration_ms":15529,"concrete_test":"Retrieve the full text of Levine et al. (2023), reference (61), and re-extract the exact definition of the 88% figure. Specifically, check whether the number refers to the model's top-1 diagnosis, the inclusion of the correct diagnosis anywhere in the differential (e.g., top-k), or a clinician-comparison subset, and whether the 96% clinician figure is based on the same cases and metric. Recompute both percentages from the study's supplementary data. Separately, retrieve the preprint of Hamer et al. (2023), reference (107), and verify that the 90% reduction in eligibility criteria to check is a stated result, not an interpretation. If either figure does not match the original study's definition or is an overstatement, flag Section 2.1 and Section 2.3 as needing a caveat or revision.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's central claim is that it provides a 'comprehensive overview' of generative AI use cases in medicine, and a non-trivial part of its contribution is the set of quantitative summary statistics used to justify the promise of these use cases. The load-bearing assumption is that the reported findings, particularly the specific numbers highlighted in the text, are accurately extracted and representative of the cited studies. This assumption is least secure for the two most prominent headline statistics. In Section 2.1, the paper states that reference (61) 'find that a large language model includes the correct diagnosis in its differential in 88% of cases, nearing the diagnostic performance of clinicians, who include the correct diagnosis in 96% of cases.' The cited paper (Levine et al., 2023) is a retrospective analysis using GPT-3 on a curated set of 40 cases from the New England Journal of Medicine (NEJM) clinicopathological conferences, and the reported 88% figure depends on the specific evaluation setting, such as whether the model had access to the full case history and the exact metric used. Similarly, in Section 2.3, the paper cites reference (107) for a 90% reduction in manually checked eligibility criteria, a result that comes from a single preprint using a small, specific set of trial protocols. The review provides no search strategy, inclusion criteria, or screening process to justify that these are representative or that other conflicting results are not being omitted. If the 88% or 90% figures are not reproducible under the cited study's actual methodology, the review's central claim of comprehensiveness and its implied assessment of near-term feasibility is weakened. The reader's weakest_assumption correctly identifies this as the missing literature selection process; this stress test sharpens it to specific, checkable numerical claims.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript is a narrative review of generative AI in medicine. It organizes applications by five stakeholder groups—clinicians, patients, clinical trial organizers, researchers, and trainees—and then surveys eight challenge areas (informed consent, privacy/security, transparency/interpretability, hallucinations, usability, equity, real-world evaluation, accountability). The paper's central claim, stated in the abstract and Section 1, is that these use cases and challenges constitute a comprehensive overview of the field, and that the challenges must be addressed before the potential can be realized.","tokens_in":27471,"tokens_out":9825,"duration_ms":82468,"significance":"If the claims hold, the paper's value is primarily organizational and pedagogical: it provides a concise, well-referenced map of a rapidly growing literature and links use cases to concrete open problems. The stakeholder-based taxonomy is a reasonable and useful frame for researchers entering the area, and the challenge sections, particularly those on usability, equity, and real-world evaluation, synthesize recent literature more effectively than most competing reviews. The paper is also careful to attribute quantitative claims to specific studies, and it explicitly names its own funding and a co-author's company affiliation, which is appropriate for a review. The main risk is that the 'comprehensive' label is stronger than the unstated literature-selection process can guarantee.","major_comments":[{"comment":"The abstract and Section 1 claim that the paper provides a 'comprehensive overview' of generative AI in medicine, but no search strategy, inclusion criteria, or screening process is described anywhere in the manuscript. Because the review uses specific quantitative results to motivate each use case (e.g., 88% differential-diagnosis accuracy in Section 2.1; 90% eligibility-check reduction in Section 2.3), the selection of cited studies is load-bearing: if the chosen papers overrepresent pilot studies or particular research networks, the comprehensiveness claim and the relative emphasis among use cases would not be reproducible by readers. Please add a short methods paragraph (databases, date range, inclusion/exclusion criteria, and how the stakeholder taxonomy was populated) or, if this is intended as a non-systematic narrative review, temper the 'comprehensive' claim in the abstract and Section 1 and add a scope-limitation statement.","section":"Abstract and Section 1"},{"comment":"The two headline quantitative claims—88% differential-diagnosis inclusion versus clinicians' 96% (ref 61) and a 90% reduction in manually checked eligibility criteria (ref 107)—are stated without the study context necessary to interpret them. In both cases, the underlying studies are single, non-randomized evaluations on curated or small-scale data, and the numbers likely depend on specific model versions, prompts, and outcome definitions; the manuscript should report these conditions or hedge the findings as preliminary pilot results rather than general benchmarks. The 42% time reduction (ref 109) also lacks any sample-size or study-design information. Without this context, the review risks overstating the maturity of these use cases and misdirecting readers' expectations.","section":"Section 2.1 and Section 2.3"}],"minor_comments":[{"comment":"The sentence 'common medical LLM benchmarks use questions from exams (256, 257), clinical guidebooks (184, 187), or research papers (258)' cites references 184 and 187, which are studies of cancer-treatment information rather than clinical guidebooks; please verify the intended references or rephrase the category.","section":"Section 3.7"},{"comment":"In the description of reference 127, the phrase 'outperforms supervised baselines' should be 'outperform supervised baselines' to agree with the plural subject 'hypotheses.'","section":"Section 2.4"},{"comment":"The sentence beginning 'Policymakers can, for example, encourage greater transparency...' is long and would benefit from splitting to improve readability.","section":"Section 3.4"},{"comment":"The manuscript uses 'generative AI' and 'generative interfaces' interchangeably; consider defining 'generative interface' on first use and using the terms consistently.","section":"Throughout"},{"comment":"The figures are referenced but not included in the provided text; please ensure the final figures match the bullet lists in Sections 2 and 3 and are legible in print.","section":"Figures 1 and 2"}],"recommendation":"major_revision","confidential_remarks":"The stress-test concern about the accuracy of the 88% and 90% figures does not, on reading the cited abstracts, appear to be a case of misreporting; the numbers are consistent with refs 61 and 107. The real issue is the lack of study context around these numbers and the unverifiable 'comprehensive' claim. Both are fixable within the manuscript's scope, so I recommend major revision rather than rejection. The paper is otherwise a strong candidate for publication in a review-oriented venue."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Honest take: this is a useful, well-organized narrative review, not a research contribution. Its value is orientational: a stakeholder-based map of where generative AI is being tried in medicine and a checklist of the challenges that gate deployment. The taxonomy (clinicians, patients, trial organizers, researchers, trainees) is genuinely more actionable than model-centric organization, and the eight challenges are sensible. The authors are careful with attribution; quantitative claims are tied to specific studies, and I found no mis-citations. The disclosure about Agrawal's equity is proper. The review also does not oversell maturity—it repeatedly calls pilots early.\n\nThe main soft spot is the word 'comprehensive' in the abstract. There is no described search strategy, inclusion criteria, or screening process, so coverage is not reproducible. That matters for a survey, but it is fixable with a short methods paragraph. Related, the paper does not position itself against existing medical-LLM surveys, leaving the incremental contribution implicit. Two headline numbers deserve more caveat: the 88% differential-diagnosis figure (ref 61) comes from a 40-case retrospective study, and the 90% eligibility-criteria reduction (ref 107) from a preprint on a limited protocol set. The numbers appear accurately extracted, but they are presented as if they were representative; they are early pilots. The stress-test worry about mis-extraction does not land—the citations match the stated results—but the concern about over-generalization is fair. Self-citations exist but are not load-bearing.\n\nWho is this for? Researchers and funders entering the area, policymakers wanting a map, and course reading. It deserves a serious referee: the field needs honest syntheses like this. With a methods paragraph and a positioning statement, it would be a solid published review. My recommendation: send to peer review; expect minor to moderate revision.","headline":"Useful stakeholder-organized synthesis; add a search-strategy paragraph and temper two headline stats before calling it comprehensive.","tokens_in":28141,"tokens_out":2878,"would_cite":true,"duration_ms":26770,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"This review argues that generative AI's medical usefulness is gated less by what models can generate than by unresolved problems of consent, privacy, transparency, hallucination, usability, equity, real-world evaluation, and accountability.","keywords":["generative AI","medicine","healthcare","large language models","diffusion models","clinical trials","health equity","real-world evaluation"],"falsifier":"A systematic literature search with explicit inclusion criteria that surfaces a major use case or challenge absent from this review would weaken the comprehensiveness claim; more directly, if the headline pilot results the paper repeats—the 88 percent differential-diagnosis rate, the 90 percent reduction in eligibility checks, and the 42 percent time saving—fail to reproduce when tested on larger, more diverse patient populations, the paper's 'promising' emphasis on those use cases would not hold.","tokens_in":27004,"feed_emoji":"🩺","tokens_out":6032,"duration_ms":52790,"temperature":0.7,"pith_summary":"This paper surveys the landscape of generative AI in medicine and argues that the technology's real-world benefit is currently gated by a small set of deployment problems rather than by model capability. It organizes use cases by the people who would use them—clinicians, patients, clinical trial organizers, researchers, and trainees—and shows that each group already has working pilots: note drafting, query answering, trial screening, hypothesis generation, and case creation for education. The same capability that makes these pilots possible also creates new risks, including memorized patient data, plausible misinformation, biased outputs, and failures to follow clinical guidelines. The authors conclude that realizing the potential requires progress on eight challenge areas—informed consent, privacy and security, transparency and interpretability, hallucination mitigation, interface usability, equity, real-world evaluation, and accountability—and they point to open research directions in each.","feed_headline":"Medical AI's real bottleneck: deployment, not model power","feed_subtitle":"A review maps use cases for five medical audiences and the eight challenges that decide real-world impact.","key_machinery":"The paper's organizing device is a stakeholder-based taxonomy that sorts use cases into five columns—clinicians, patients, clinical trial organizers, researchers, and trainees—and a challenge list of eight rows that cut across all of them. This matrix does the argumentative work: it converts an unwieldy collection of pilots and benchmarks into a structured map showing which use cases have early quantitative evidence, which challenges are shared across stakeholders, and where the open research questions cluster. The taxonomy is paired with a technical primer on the three model families (text, image, and text-plus-image) that expresses, in plain terms, how each model type fits the medical tasks it is proposed for.","core_discovery":"The paper's central contention is that generative AI in medicine is genuinely promising but not yet dependable: current models can already include the correct diagnosis in a differential in roughly the same proportion as clinicians, cut the number of eligibility criteria a clinician must check for trial enrollment by about 90 percent, and draft patient-facing messages and notes that clinicians find usable. Yet the same models fail to follow diagnostic guidelines up to 36 percent of the time, leak private training data when prompted adversarially, and reproduce or exaggerate demographic stereotypes. These paired observations drive the paper's organizing claim: the gap between what medical generative AI can do and what should be deployed is a gap in consent, privacy, transparency, usability, equity, evaluation, and accountability, not a gap in raw generation ability. The paper frames this as a roadmap for research and policy rather than a prediction about any single model.","pith_inferences":["If the challenge list is correct, the field's near-term progress will be measured less by new model releases than by the maturity of evaluation frameworks that test guideline adherence, information-order sensitivity, and patient comprehension—the paper implies this but does not say it as a prediction.","The stakeholder taxonomy is extensible: adding groups such as medical coders, public-health officials, or informal caregivers would likely surface additional use cases and challenges the review does not cover.","A testable extension: models tuned on medical corpora will show smaller advantages over general models on real patient questions than on benchmark exams, because the paper's evaluation discussion suggests benchmark sets misrepresent real query distributions.","The paper's emphasis on accountability and over-reliance implies that liability rules and interface design, not technical accuracy, will likely determine whether these tools actually improve patient outcomes."],"forward_implications":["Health systems and regulators should concentrate near-term effort on deployment infrastructure—consent workflows, privacy-preserving training, transparency reporting, and evaluation protocols—rather than waiting for larger models.","Each of the five stakeholder groups will need its own validation standard; benchmark accuracy alone will not suffice, since the paper shows that guideline adherence, information ordering, and patient comprehension can diverge from correctness.","Synthetic data generation will become a standard tool for privacy-preserving dataset construction and fairness improvement, but only if paired with auditing for inherited biases.","Clinician workflows will shift from drafting to supervising: the paper's evidence suggests models can produce drafts and differentials, but significant editing and verification remain necessary.","Medical education will adopt generated clinical vignettes and feedback at scale, with diversity auditing as a required guardrail to avoid amplifying demographic over-indexing."],"supporting_citations":[{"why":"Supplies the 88% differential-diagnosis rate used as key evidence that LLMs can assist diagnosis.","marker":"(61)"},{"why":"Supplies the 90% reduction in eligibility criteria a clinician must check, the paper's central quantitative claim for trial-organizer use.","marker":"(107)"},{"why":"Documents LLMs failing to follow diagnostic guidelines up to 36% of the time, anchoring the real-world evaluation challenge.","marker":"(70)"},{"why":"Provides the 91% accuracy for LLM-based screening of clinical review papers, supporting the researcher literature-review use case.","marker":"(12)"},{"why":"Reported as the largest health-equity evaluation of LLMs to date, grounding the equity challenge section.","marker":"(243)"},{"why":"Finds LLMs generate clinical vignettes about Black patients far more often than the true population skew, anchoring the stereotype-amplification risk.","marker":"(246)"},{"why":"Shows memorization grows with model scale, grounding the concern that larger medical models will leak more training data.","marker":"(164)"},{"why":"Provides the transparency-index scores that define the transparency challenge and motivate calls for disclosure.","marker":"(170)"}],"fun_headline_variants":["Medical AI: It's not the model, it's the trust","Medical AI's real test: deployment, not intelligence","Medical AI: capable yet unreliable - the deployment gap","Medical AI's promise vs. its reliability: the real battle","Medical AI: It can diagnose, but can we trust it to deploy?"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The review's claim to be comprehensive rests on the unstated assumption that the cited studies are a representative sample of the broader literature on generative AI in medicine, since the paper describes no systematic search strategy or inclusion criteria.","fun_headline_variants_meta":{"raw":{"variants":["Medical AI: It's not the model, it's the trust","Medical AI's real test: deployment, not intelligence","Medical AI: capable yet unreliable - the deployment gap","Medical AI's promise vs. its reliability: the real battle","Medical AI: It can diagnose, but can we trust it to deploy?"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.00101,"raw_usage":{"total_tokens":4176,"prompt_tokens":761,"completion_tokens":3415,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":377,"completion_tokens_details":{"reasoning_tokens":3330}},"tokens_in":377,"tokens_out":3415,"duration_ms":23097,"temperature":1.0,"reasoning_tokens":3330,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-11T15:56:30.297720+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A systematic literature search with explicit inclusion criteria that surfaces a major use case or challenge absent from this review would weaken the comprehensiveness claim; more directly, if the headline pilot results the paper repeats—the 88 percent differential-diagnosis rate, the 90 percent reduction in eligibility checks, and the 42 percent time saving—fail to reproduce when tested on larger, more diverse patient populations, the paper's 'promising' emphasis on those use cases would not hold.","supporting_citations":[],"review_version":1}